Skip to main content
SpringerLink
Log in

Durchblutungsfördernde Mittel

  • Chapter
Book cover Arzneiverordnungs-Report 1999

  • 43 Accesses

Zusammenfassung

Durchblutungsfördernde Mittel werden bei peripheren und zerebralen Durchblutungsstörungen eingesetzt. Die Mehrzahl der Präparate ist nur noch für die Anwendung bei peripheren arteriellen Durchblutungsstörungen zugelassen. Diese indikative Abgrenzung ist vor allem dadurch entstanden, daß zahlreiche Herstellerfirmen ihre Präparate ab 1996 zusammen mit den Nootropika in eine neu geschaffene Indikationsgruppe „Antidementiva“ umgruppiert haben (s. Kapitel 7).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Adhoute G., Andreassian B., Boccalon H., Cloarec M., Di Maria G. et al. (1990): Treatment of stage II chronic arterial disease of the lower limbs with the serotonergic antagonist naftidrofuryl: results after 6 months of a controlled, multicenter study. J. Cardiovasc. Pharmacol. 16 (Suppl. 3): S75–S80.

    PubMed  Google Scholar 

  • Adhoute G., Bacourt F., Barral M., Cardon J.M., Chevalier J.M. et al. (1986): Naftidrofuryl in chronic arterial disease. Results of a six month controlled multicenter study using naftidrofuryl tablets 200 mg. Angiology 37: 160–167.

    Article  PubMed  CAS  Google Scholar 

  • Arzneimittelkommission der Deutschen Apotheker (1995): Naftidrofuryl Infusionslösung. Pharmazeut. Ztg. 140: 2222.

    Google Scholar 

  • Barradell L.B., Brogden R.N. (1996): Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arte rial disease. Drugs Aging 8: 299–322.

    Article  PubMed  CAS  Google Scholar 

  • Bauer U. (1984): 6-Month double-blind randomised clinical trial of ginkgo biloba extract versus placebo in two parallel groups in patients suffering from peripheral arterial insufficiency. Arzneim. Forsch. 34: 716–720.

    CAS  Google Scholar 

  • Bollinger A., Frei Ch. (1977): Double-blind study of pentoxifylline against placebo in patients with intermittent claudication. Pharmatherapeutica 1: 557–563.

    Google Scholar 

  • Clifford P.C., Davies P.W., Hayne J.A., Baird R.N. (1980): Intermittent claudication: is a supervised exercise class worth while? Brit. Med. J. 280: 1503–1505.

    Article  PubMed  CAS  Google Scholar 

  • Cummings D.M., Ballas S.K., Ellison M.J. (1992): Lack of effect of pentoxifylline on red blood cell deformability. J. Clin. Pharmacol. 32: 1050–1053.

    Article  PubMed  CAS  Google Scholar 

  • Dahllöf A.-G., Holm J., Scherstén T., Sivertsson R. (1976): Peripheral arterial insufficiency. Effect of physical training on walking tolerance, calf blood flow, and blood flow resistance. Scand. J. Rehab. Med. 8: 19–26.

    Google Scholar 

  • Dettori A.G., Pini M., Moratti A., Paolicelli M., Basevi P. et al. (1989): Acenocoumarol and pentoxifylline in intermittent claudication. A controlled clinical study. Angiology. 40: 237–248.

    Article  PubMed  CAS  Google Scholar 

  • Di Perri T., Carandente 0., Vittoria A., Guerrini M., Messsa G.L. (1984): Studies of the clinical pharmacology and therapeutic efficacy of pentoxifylline in peripheral obstructive arterial disease. Angiology 35: 427–435.

    Article  PubMed  Google Scholar 

  • Donaldson D.R., Hall T.J., Kester R.C., Ramsden C.W., Wiggins P.A. (1984): Does oxpentifylline (‚Trental‘) have a place in the treatment of intermittent claudication? Curr. Med. Res. Opin. 9: 35–40.

    Article  PubMed  CAS  Google Scholar 

  • Drabrek H., Petersen J.R., Winberg N., Hansen K.F., Mehlsen J. (1996): The effect of Ginkgo biloba extract in patients with intermittent claudication. Ugeskr. Laeger 158: 3928–3931.

    Google Scholar 

  • Ekroth R., Dahllöf A.-G., Gundevall B., Holm J., Schersten T. (1978): Physical training of patients with intermittent claudication: indications, methods, and results. Surgery 84: 640–643.

    PubMed  CAS  Google Scholar 

  • Ernst E., Kollar L., Resch K.L. (1992): Does pentoxifylline prolong the walking distance in exercised claudicants? A placebo-controlled double-blind trial. Angiology 43: 121–125.

    Article  PubMed  CAS  Google Scholar 

  • Ernst E. (1994): Pentoxifylline for intermittent claudication. A critical review. Angiology 45: 339–345.

    Article  PubMed  CAS  Google Scholar 

  • Gallus A.S., Morley A.A., Dupont P., Walsh H., Gleadow F. et al. (1985): Intermittent claudication: a double-blind study crossover trial of pentoxifylline. Aust. N. Z. J. Med. 15: 402–409.

    Article  PubMed  CAS  Google Scholar 

  • Girolami B., Bernardi E., Prins M. H., Wouter ten Cate J., Hettiarachchi R. et al. (1999): Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl. Arch. Intern. Med. 159: 337–345.

    Article  PubMed  CAS  Google Scholar 

  • Heidrich H., Allenberg J., Cachovan M., Creutzig A., Diehm C. et al. (1992): Prüfrichtlinien für Therapiestudien im Fontaine-Stadium II-IV bei peripher-arterieller Verschlußkrankheit. Vasa 21: 333–337.

    PubMed  CAS  Google Scholar 

  • Housley E. (1988): Treating claudication in five words. Brit. Med. J. 296: 1483–1484.

    Article  CAS  Google Scholar 

  • Jonason T., Jonzon B., Ringqvist I., Öman-Rydberg A. (1979): Effect of physical training on different categories of patients with intermittent claudication. Acta Med. Scand. 206: 253–258.

    Article  PubMed  CAS  Google Scholar 

  • Karnik R., Valentin A., Stöllberger C., Slany J. (1988): Effects of naftidrofuryl in patients with intermittent claudication. Angiology 39: 234–240.

    Article  PubMed  CAS  Google Scholar 

  • Kiesewetter H., Blume J., Jung E, Gerhards M., Leipnitz G. (1987): Gehtraining und medikamentöse Therapie bei der peripheren arteriellen Verschlußkrankheit. Randomisierte, prospektive, placebo-kontrollierte Doppelblindstudie. Dtsch. Med. Wochenschr. 112: 873–878.

    Article  PubMed  CAS  Google Scholar 

  • Laporte J.R., Capella D. (1986): Useless drugs are not placebos: Lessons from flunarizine and cinnarizine. Lancet 2: 853–854.

    Google Scholar 

  • Larsen O.A., Lassen N.A. (1966): Effect of daily muscular exercise in patients with inter mitte nt claudication. Lancet 2: 1093–1096.

    Article  PubMed  CAS  Google Scholar 

  • Lindgärde E, Jelnes R., Björkman H., Adielsson G., Kjellström T. et al. (1989): Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arte rial disease. Circulation 80: 1549–1556.

    Article  PubMed  Google Scholar 

  • Maass U., Amberger H.-G., Böhme H., Diehm C., Dimroth H. et al. (1984): Naftidrofuryl bei arterieller Verschlußkrankheit. Dtsch. Med. Wochenschr. 19: 745–750.

    Article  Google Scholar 

  • Pedersen T.R., Kjekshus J., Pyörälä K., Olsson A.G., Cook T.J. et al. (1998): Effect of Simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am. J. Cardiol. 81: 333–335.

    Article  PubMed  CAS  Google Scholar 

  • Porter J.M., Cutler B.S., Lee B.Y., Reich Th., Reichle EA. et al. (1982): Pentoxifylline efficacy in the treatment of inter mitte nt claudication. Multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am. Heart J. 104: 66–72.

    Article  PubMed  CAS  Google Scholar 

  • Quick C.R., Cotton L.T. (1982): The measured effect of stopping smoking on intermittent claudication. Brit. J. Surg. 69 (Suppl.): S24–S26.

    Article  PubMed  Google Scholar 

  • Radack K., Wyderski R.J. (1990): Conservative management of intermittent claudication. Ann. Intern. Med. 113: 135–146.

    Article  PubMed  CAS  Google Scholar 

  • Rieger H., Hossmann V. (1998): Medikamentöse Durchblutungssteigerung bei chronischer peripherer arterieller Verschlußkrankheit. In: Rieger H., Schoop W. (Hrsg.): Lehrbuch der Angiologie. Springer Verlag Berlin Heidelberg NewYork, S.239–252.

    Google Scholar 

  • Roekaerts E, Deleers L. (1984): Trental® 400 in the treatment of intermittent claudication: results of long-term, placebo-controlled administration. Angiology 35: 396–406.

    Article  PubMed  CAS  Google Scholar 

  • Scandinavian Simvastatin Survival Study Group (1994): Randomized trial of cholesterollowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383–1389.

    Google Scholar 

  • Scheffler A., Rieger H. (1999): Arterielle Durchblutungsstörungen. In: Paumgartner G. (Hrsg.) Therapie innerer Krankheiten 9. Aufl., Springer Verlag, Berlin Heidelberg New York, S. 257–273.

    Chapter  Google Scholar 

  • Scheffler P., de la Harnette D., Gross J., Mueller H., Schieffer H. (1994): Intensive vascular training in stage IIb of peripheral arterial occlusive disease. The additive effects of intravenous prostagiandin E1 or intravenous pentoxifylline during training. Circulation 90: 818–822.

    Article  PubMed  CAS  Google Scholar 

  • Schoop W., Breddin K., Diehm C., Gruß J., Held K. et al.: Klinische Prüfung mit Ginkgo biloba-Spezialextrakt Egb 761 bei Patienten mit peripherer arterieller Verschlußkrankheit im Stadium II b nach Fontaine im Vergleich zu Placebo. In Vorbereitung.

    Google Scholar 

  • Strano A., Davi G., Avellone G., Novo S., Pinto A. (1984): Double-blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease of the lower limbs. Angiology 35: 459–466.

    Article  PubMed  CAS  Google Scholar 

  • Transparenzkommission (1983): Transparenzliste für das Teilgebiet periphere arterielle Durchblutungsstörungen. Bundesanzeiger Nr. 169 vom 9.9.1983.

    Google Scholar 

  • Walker G.A. MacMannaford J.C. (1995): A meta-analysis of randomized, doubleblind, placebo-controlled studies of the effect of buflomedil on intermittent claudication. Fundam. Clin. Pharmacol. 9: 387–394.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. U. Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg, Deutschland

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln, Deutschland

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Schwabe, U. (2000). Durchblutungsfördernde Mittel. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 1999. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-57215-9_24

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-57215-9_24

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-66376-8

  • Online ISBN: 978-3-642-57215-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation